On January 22, 2026, Cathie Wood–led Ark Invest deployed approximately $2.4 million to acquire 13,532 shares of Tempus AI across its Genomic Revolution and Innovation ETFs. This follows a larger purchase of roughly $5.85 million in Tempus AI shares just one day earlier, underscoring Ark’s conviction in the company’s growth trajectory. The move comes after independent research firms upgraded coverage on Tempus AI, highlighting its robust diagnostics revenue and market positioning.

Tempus AI reported preliminary full-year 2025 revenue growth of 83% compared with the prior year, driven by a 111% increase in diagnostics revenue. The company also reached $1.1 billion in total contract value, securing over 70 data and collaboration agreements with pharmaceutical partners. In Q3 2025, Tempus AI achieved its first positive adjusted EBITDA, marking a key inflection point as operating efficiencies improved and volume in next-generation sequencing and digital pathology services ramped up.

In early 2026, Tempus AI introduced Paige Predict, a suite of AI-powered digital pathology applications designed to analyze hematoxylin and eosin whole-slide images and predict the presence of 123 clinically actionable biomarkers across 16 cancer types. Built on a combined, de-identified dataset of over 200,000 patient records from Tempus and its subsidiary Paige, the solution delivers predictive biomarker insights directly to physicians’ reports, reducing the need for repeat biopsies and expediting treatment decisions when tissue samples are limited.